Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that revenue once again grew at double-digit rates thanks to increased demand for Vivitrol and Aristada. In addition, the company continues to make steady progress at moving its late-stage product candidates one step closer to the finish line.
Image source: Getty images.
Data source: Alkermes. GAAP = generally accepted accounting principles. EPS = earnings per share. NM = not meaningful due to negative figures.
Source: Fool.com
Alkermes plc Aktie
24,00 €
-4,76 %
Des weiteren hat Alkermes plc derzeit 17 Buy-Einschätzungen und 2 Sell-Einschätzungen durch unsere Community zu Buche stehen.
Das Kursziel von 35 € für Alkermes plc bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 24.0 €.
